Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2232423 | 0.99 | BRD4 (0.31) | BRD4CREBBPNPC1LMNATP53 | |
| SCHEMBL22411948 | 0.94 | — | — | |
| SCHEMBL3700473 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL2233539 | 0.90 | — | — | |
| SCHEMBL6459300 | 0.90 | — | — | |
| SCHEMBL22411218 | 0.89 | — | — | |
| SCHEMBL3681017 | 0.89 | RXRA (0.30) | — | |
| SCHEMBL11967835 | 0.88 | — | — | |
| Chloromethane SCHEMBL8460737 | 0.88 | ENPP1 (0.32) | — | |
| SCHEMBL5584002 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799726-B1 | TRIALKYLALUMINUM TREATED SUPPORTS | EXXONMOBIL CHEM PATENTS INC (US) | 2011-07-13 | — | — | EP | claimed |
| US-20090221772-A1 | Bridged bis indenyl ligands where the indene ring is further fused to an oxygen or sulfur-containing ring, such as mu -{Bis-[ eta 5-8-(4-tert-butylphenyl)-6-methyl-5H-indeno[5,6-a][1,3]dioxol-5-yl]dimethylsilanediyl}dichlorozirconium; olefin polymerization catalysts; very high molecular weight | BASELL POLYLEFINE GMBH (DE) | 2009-09-03 | — | — | US | disclosed |
| EP-1549688-A2 | PROCESS FOR THE COPOLYMERIZATION OF ETHYLENE | Basell Polyolefine GmbH (DE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004033510-A2 | PROCESS FOR THE COPOLYMERIZATION OF ETHYLENE | BASELL POLYOLEFINE GMBH (DE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221772-A1 | Bridged bis indenyl ligands where the indene ring is further fused to an oxygen or sulfur-containing ring, such as mu -{Bis-[ eta 5-8-(4-tert-butylphenyl)-6-methyl-5H-indeno[5,6-a][1,3]dioxol-5-yl]dimethylsilanediyl}dichlorozirconium; olefin polymerization catalysts; very high molecular weight | LTC4S, HMOX1, OPRM1 | BRD4 607/4885CREBBP 4749/4885NPC1 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.